Open-label, Investigator-initiated, Single-site Proof of Concept Trial Evaluating EVO101 in Adult Subjects with Mild to Moderate Hidradenitis Suppurativa.
Latest Information Update: 16 Dec 2024
Price :
$35 *
At a glance
- Drugs EVO 101 (Primary)
- Indications Hidradenitis suppurativa
- Focus Proof of concept; Therapeutic Use
- 11 Dec 2024 Status changed from not yet recruiting to recruiting.
- 22 Oct 2024 New trial record